Skip to main content

Table 3 Costs, life-years and incremental cost per life-year gained

From: Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

First-line treatment Cost per loading dose (£) Cost per maintenance dose (£) Total costs (£) Incremental costs (£) Total no. life years Incremental no. life years Incremental cost-effectiveness ratio
IV IV Oral
Anidulafungin 600.0 300.0 - 28,216 7.23
Fluconazole 7.8 7.8 1.4 27,646 −570 6.52 −0.70 813
Caspofungin 416.8 367.2 - 28,905 689 6.03 −1.19 Dominateda
Micafungin 341.0 341.0 - 28,721 504 5.55 −1.68 Dominateda
  1. The incremental cost-effectiveness ratio calculated was the incremental cost per life year gained. All incremental cost-effectiveness ratios were calculated as anidulafungin vs comparator
  2. aFirst-line treatment with anidulafungin was less costly and more effective than the comparator, thus first-line treatment with anidulafungin dominated the comparator